Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
Sara Olofsson, Hanna Norrlid & Ulf Persson. (2016) Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden. Journal of Medical Economics 19:10, pages 945-958.
Read now
Read now
Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso & Maribel Tribaldos Causadias. (2015) Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference and Adherence 9, pages 1443-1458.
Read now
Read now
Charles F Shaefer$suffix/text()$suffix/text(), Pamela Kushner & Richard Aguilar. (2015) User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine 127:8, pages 818-826.
Read now
Read now
Anthony H. Barnett. (2013) Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus. Postgraduate Medicine 125:5, pages 92-100.
Read now
Read now
J. Jendle, O. Torffvit, M. Ridderstråle, Å. Ericsson, B. Nilsen & M. Bøgelund. (2012) Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. Journal of Medical Economics 15:sup2, pages 1-5.
Read now
Read now
Asger Lund & Filip K. Knop. (2012) Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Current Medical Research and Opinion 28:5, pages 731-736.
Read now
Read now
Articles from other publishers (47)
Beverley M. Shields, Catherine D. Angwin, Maggie H. Shepherd, Nicky Britten, Angus G. Jones, Naveed Sattar, Rury Holman, Ewan R. Pearson & Andrew T. Hattersley. (2022) Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. Nature Medicine 29:2, pages 384-391.
Crossref
Crossref
Yuankai Huang, Qixiang Huang, Ailin Xu, Mengqing Lu & Xiaoyu Xi. (2022) Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Frontiers in Public Health 9.
Crossref
Crossref
Louis S. Matza, Katelyn N. Cutts, Katie D. Stewart, Kirsi Norrbacka, Luis-Emilio García-Pérez & Kristina S. Boye. (2021) Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research 30:7, pages 2033-2043.
Crossref
Crossref
Laura Canals-Ruiz, Marta Comellas & Luís Lizán. (2021) Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature. Journal of Comparative Effectiveness Research 10:8, pages 629-645.
Crossref
Crossref
Sreenivasa Murthy, Pankaj Aneja, Arthur Joseph Asirvatham, Lise Lotte N. Husemoen, Nicolai A. Rhee & Jothydev Kesavadev. (2021) Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market. PharmacoEconomics - Open 5:2, pages 261-273.
Crossref
Crossref
Ahuja Nirmal, Kristin Sznajder, Rajendra Patil & Bushra Shaikh. (2021) Preference of inhalants over pills/injections among pulmonary tuberculosis patients in Western India: A cross-sectional study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 23, pages 100234.
Crossref
Crossref
Marloes Dankers, Marjorie H. J. M. G. Nelissen‐Vrancken, Bertien H. Hart, Anke C. Lambooij, Liset Dijk & Aukje K. Mantel‐Teeuwisse. (2021) Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals’ preferences. Pharmacology Research & Perspectives 9:3.
Crossref
Crossref
Axel C. Mühlbacher, Andrew Sadler & Christin Juhnke. (2021) Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. The European Journal of Health Economics 22:3, pages 425-443.
Crossref
Crossref
Kristina Boye, Melissa Ross, Reema Mody, Manige Konig & Heather Gelhorn. (2020)
Patients' preferences for
once‐daily
oral versus
once‐weekly
injectable diabetes medications: The
REVISE
study
. Diabetes, Obesity and Metabolism 23:2, pages 508-519.
Crossref
Crossref
Semra Ozdemir, Drishti Baid, Naina R. Verghese, Amanda YR. Lam, Phong Ching Lee, Adoree YY. Lim, Ling Zhu, Sonali Ganguly, Eric A. Finkelstein & Su-Yen Goh. (2020) Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. Value in Health 23:7, pages 842-850.
Crossref
Crossref
Mahdi Toroski, Abbas Kebriaeezadeh, Alireza Esteghamati, Ali Kazemi Karyani, Hadi Abbasian & Shekoufeh Nikfar. (2019) Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes & Metabolic Disorders 18:2, pages 643-656.
Crossref
Crossref
Christin Juhnke & Axel C. Mühlbacher. (2019) Patientenpräferenzen: Wünsche von Betroffenen mit Diabetes mellitusPatient preferences: what do diabetes patients want?. Der Diabetologe 15:6, pages 534-541.
Crossref
Crossref
Marta Trapero-Bertran, Beatriz Rodríguez-Martín & Julio López-Bastida. (2019) What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review. PLOS ONE 14:7, pages e0219905.
Crossref
Crossref
Simon Fifer, John Rose, Kim K. Hamrosi & Dan Swain. (2018) Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Services Research 18:1.
Crossref
Crossref
M. Y. L. Siaw, D. C. Malone, Y. Ko & J. Y.-C. Lee. (2018) Cost-effectiveness of multidisciplinary collaborative care versus usual care in the management of high-risk patients with diabetes in Singapore: Short-term results from a randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics 43:6, pages 775-783.
Crossref
Crossref
L. Mc Morrow, M. C. O’ Hara, L. Hynes, Á. Cunningham, A. Caulfield, C. Duffy, C. Keighron, M. Mullins, M. Long, D. Walsh, M. Byrne, B. Kennelly, P. Gillespie, S. F. Dinneen & E. Doherty. (2018) The preferences of young adults with Type 1 diabetes at clinics using a discrete choice experiment approach: the D1 Now Study. Diabetic Medicine 35:12, pages 1686-1692.
Crossref
Crossref
G. Forsander, S. Stallknecht, U. Samuelsson, C. Marcus & M. Bøgelund. (2018) Preferences for treatment among adolescents with Type 1 diabetes: a national study using a discrete choice experiment model. Diabetic Medicine 35:5, pages 621-629.
Crossref
Crossref
Zhiying Wang, Jiahui Sun, Ruobing Han, Dongzhu Fan, Xinyi Dong, Zenghui Luan, Rongwu Xiang, Mingyi Zhao & Jingyu Yang. (2017)
Efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as monotherapy or add‐on to metformin in patients with type 2 diabetes mellitus:
A
systematic review and meta‐analysis
. Diabetes, Obesity and Metabolism 20:1, pages 113-120.
Crossref
Crossref
Ellen M. Janssen, A. Brett Hauber & John F.P. Bridges. (2018) Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Value in Health 21:1, pages 59-68.
Crossref
Crossref
M. C. O’Hara, L. Hynes, M. O’Donnell, C. Keighron, G. Allen, A. Caulfield, C. Duffy, M. Long, M. Mallon, M. Mullins, G. Tonra, M. Byrne & S. F. Dinneen. (2017) Strength in Numbers: an international consensus conference to develop a novel approach to care delivery for young adults with type 1 diabetes, the D1 Now Study. Research Involvement and Engagement 3:1.
Crossref
Crossref
J. Carlton, J. Elliott, D. Rowen, K. Stevens, H. Basarir, K. Meadows & J. Brazier. (2017) Developing a questionnaire to determine the impact of self-management in diabetes: giving people with diabetes a voice. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado & Kristina S. Boye. (2017) Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics 39:11, pages 2284-2295.
Crossref
Crossref
Anna Rydén, Stephanie Chen, Emuella Flood, Beverly Romero & Susan Grandy. (2017) Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus. The Patient - Patient-Centered Outcomes Research 10:4, pages 475-487.
Crossref
Crossref
Lill-Brith von Arx, F. Reed Johnson, Morten Raun Mørkbak & Trine Kjær. (2017) Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients’ Benefit-Risk Tradeoff Preferences. Value in Health 20:4, pages 670-678.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy 8:2, pages 335-353.
Crossref
Crossref
Eirik Søfteland, Juris J. Meier, Bente Vangen, Robert ToorawaMario Maldonado-Lutomirsky & Uli C. Broedl. (2017) Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care 40:2, pages 201-209.
Crossref
Crossref
Martin Ridderstråle, Lyndon Marc Evans, Henrik Holm Jensen, Mette Bøgelund, Marie Markert Jensen, Åsa Ericsson & Johan Jendle. (2016) Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health and Quality of Life Outcomes 14:1.
Crossref
Crossref
James Buchanan, Sarah Wordsworth & Anna Schuh. (2016) Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment. The Patient - Patient-Centered Outcomes Research 9:6, pages 525-536.
Crossref
Crossref
Axel Mühlbacher & Susanne Bethge. (2015) What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. The European Journal of Health Economics 17:9, pages 1125-1140.
Crossref
Crossref
Juan José Gorgojo Martínez. (2016) Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visión adipocéntrica del abordaje de la diabetes. Medicina Clínica 147, pages 8-16.
Crossref
Crossref
Ellen M. Janssen, Jodi B. Segal & John F. P. Bridges. (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 9:5, pages 465-479.
Crossref
Crossref
Narayan Rajan, Kristina S. Boye, Meaghan Gibbs, Yoon Ji Lee, Peter Davey, Mark Ball & Steve M. Babineaux. (2016) Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population. Value in Health Regional Issues 9, pages 67-71.
Crossref
Crossref
Inger M. Janssen, Ansgar Gerhardus, Milly A. Schröer-Günther & Fülöp Scheibler. (2015) A descriptive review on methods to prioritize outcomes in a health care context. Health Expectations 18:6, pages 1873-1893.
Crossref
Crossref
Ugne Sabale, Johan Bodegård, Johan Sundström, Carl Johan Östgren, Peter Nilsson, Gunnar Johansson, Bodil Svennblad & Martin Henriksson. (2015) Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting. Primary Care Diabetes 9:5, pages 330-337.
Crossref
Crossref
Tsung-Tai Chen, Tao-Hsin Tung, Ya-Seng (Arthur) Hsueh, Ming-Han Tsai, Hsiu-Mei Liang, Kay-Lun Li, Kuo-Piao Chung & Chao-Hsiun Tang. (2015) Measuring Preferences for a Diabetes Pay-for-Performance for Patient (P4P4P) Program using a Discrete Choice Experiment. Value in Health 18:5, pages 578-586.
Crossref
Crossref
Peter G. M. Mol, Arna H. Arnardottir, Sabine M. J. Straus, Pieter A. de Graeff, Flora M. Haaijer-Ruskamp, Elise H. Quik, Paul F. M. Krabbe & Petra Denig. (2015) Understanding drug preferences, different perspectives. British Journal of Clinical Pharmacology 79:6, pages 978-987.
Crossref
Crossref
Axel C. Mühlbacher & A. Kaczynski. (2015) Patientenpräferenzen in der medikamentösen Therapie von Diabetes Mellitus Typ 2Patients’ preferences in the medicamentous treatment of diabetes mellitus type 2. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 58:4-5, pages 452-466.
Crossref
Crossref
Ugne Sabale, Mattias Ekman, Ola Granström, Klas Bergenheim & Phil McEwan. (2015) Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes 9:1, pages 39-47.
Crossref
Crossref
Johanna O P Wanders, Jorien Veldwijk, G Ardine de Wit, Huberta E Hart, Paul F van Gils & Mattijs S Lambooij. (2014) The effect of out-of-pocket costs and financial rewards in a discrete choice experiment: an application to lifestyle programs. BMC Public Health 14:1.
Crossref
Crossref
A. Higgins, J. Barnett, C. Meads, J. Singh & L. Longworth. (2014) Does Convenience Matter in Health Care Delivery? A Systematic Review of Convenience-Based Aspects of Process Utility. Value in Health 17:8, pages 877-887.
Crossref
Crossref
Michael D. Clark, Domino Determann, Stavros Petrou, Domenico Moro & Esther W. de Bekker-Grob. (2014) Discrete Choice Experiments in Health Economics: A Review of the Literature. PharmacoEconomics 32:9, pages 883-902.
Crossref
Crossref
Lill-Brith von Arx & Trine Kjær. (2014) The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. The Patient - Patient-Centered Outcomes Research 7:3, pages 283-300.
Crossref
Crossref
Tanjala S. Purnell, Susan Joy, Emily Little, John F.P. Bridges & Nisa Maruthur. (2014) Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review. Diabetes Care 37:7, pages 2055-2062.
Crossref
Crossref
S. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood & A. H. Barnett. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 433-442.
Crossref
Crossref
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle & Uli C Broedl. (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology 1:3, pages 208-219.
Crossref
Crossref
A.F. Mohamed, J. Zhang, F.R. Johnson, I. Duprat Lomon, E. Malvolti, R. Townsend, C.J. Östgren & K.G. Parhofer. (2013) Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: Patient preferences. Diabetes & Metabolism 39:5, pages 397-403.
Crossref
Crossref
Susan M. Joy, Emily Little, Nisa M. Maruthur, Tanjala S. Purnell & John F. P. Bridges. (2013) Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review. PharmacoEconomics 31:10, pages 877-892.
Crossref
Crossref